Novogen spannend - 500 Beiträge pro Seite

[DomRuinart]

Hier kann man mal mit einer kleinen Position mitzocken. Wenn das was dieser Dr. Kelly und die Universität Yale zur Pipeline publizieren auch nur ansatzweise stimmt, dann könnten die wirklich den Stein der Weisen in Sachen Krebstherapie gefunden haben und das Potential wäre gigantisch. Mit der KE scheint hier jedenfalls etwas "Smart Money" von Investoren eingeflossen zu sein und angeblich sollen noch vor Beginn der ersten klinischen Trials in Australien Mitte 2015 weitere Publikationen folgen. Ich riskier eine kleine Position, aber Achtung: sehr geringes Volumen in Deutschland mit riesigen Spreads, darum lieber direkt in US handeln.

[DomRuinart]

ASX RELEASE
7 January 2015
NOVOGEN TO CONDUCT SHAREHOLDER/INVESTOR BRIEFING IN NEW YORK
§ 2015/2016 clinical research strategy to be previewed
§ US scientists to present details of Cantrixil and TRXE-009 studies
7 January 2015, Sydney, Australia: Novogen Limited (ASX:NRT; NASDAQ:NVGN),
an Australian/US biotechnology company, today announced that it will hold a public
Briefing for shareholders and investors in New York on 18th February 2015 at 2 pm.
The briefing will be held at the Yale Club (Saybrook Room), 50 Vanderbilt Ave,
Manhattan (opposite Grand Central Terminal).
The main purpose of the Briefing is to provide an opportunity for US shareholders to
meet senior company executives and for the investment community at large to better
understand the Company’s intellectual property portfolio and commercial potential.
Dr Graham Kelly, Novogen Group CEO and Executive Chairman, will present an
overview of the clinical and corporate strategies for the Novogen Group for 2015-
2016.
Professor Gil Mor PhD MD of Yale Medical School will present a talk entitled ‘Cantrixil:
A Novel Therapy to Target Cancer Stem Cells to Prevent Tumor Recurrence.”
Dr Marc Symons PhD of the Feinstein Institute for Medical Research at North Shore-
LIJ will present a talk entitled “Development of TRXE-009 for the Treatment of Brain
Cancer.”
Dr Andrew Heaton, Novogen VP Drug Design and Manufacturing, and Mr Robert
Kennedy, Novogen VP Corporate Relations (US), also will be in attendance.
The details of the Briefing are contained in the January edition of the Novogen
Newsletter released today and available on the Company’s website.
People interested in attending will need to confirm by contacting
[e-mail]
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on
both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The
Novogen group includes US-based, CanTx Inc, a joint venture company with Yale
University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and
anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full
heterogeneity of cells within a tumor, including the cancer stem cells. The molecular
target is a trans-membrane electron-transfer pump mechanism oncogene that is
common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.
The ATM compounds target the micro-filament component of the cancer cell’s cytoskeleton and have been
designed to combine with anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and
fatal destruction of the cancer cell cytoskeleton.
The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and
one ATM drug candidate (‘Anisina’).
Further information is available on our websites

[straumen]

Antwort auf Beitrag Nr.: 48.715.397 von DomRuinart am 07.01.15 13:35:47

Bin auch mal dabei. Erste Position heute und ggf. unter 2$ nachlegen.
Wir werden sehen...

Gruß

[straumen]

Antwort auf Beitrag Nr.: 48.756.020 von straumen am 12.01.15 19:20:16

Zitat von straumen: Bin auch mal dabei. Erste Position heute und ggf. unter 2$ nachlegen.
Wir werden sehen...

Gruß

...was´n passiert. Heute 40% - finde aber keine News

[DomRuinart]

Antwort auf Beitrag Nr.: 48.787.163 von straumen am 15.01.15 15:55:44

Novogen Announces Important Discovery in Regenerative Medicine Program


SYDNEY, Jan. 15, 2015 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ: NVGN), an Australian/US biotechnology company, today announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells.

Regenerative medicine is concerned with repairing or replacing tissue lost due to age, disease, damage or congenital defects. In the case of the brain, damage associated with stroke, head trauma or neurodegenerative disease represents a very significant unmet clinical need for such therapies.

Novogen scientists now in an important scientific breakthrough have identified a family of compounds with an ability to promote the growth and activity of normal brain stem cells.

The dominant approach being taken to brain regeneration is the introduction of tissue stem cells that have been cultured outside of the body. However, delivery of these cells through the skull is very invasive and, so far, these cells seem to be susceptible to the same constraints that limit the resident stem cell population.

Work in the 1990's showed that the old adage, 'We continue to grow brain cells until age 21, and from then on it's all downhill', was, in fact, untrue. Close examination revealed that part of the hippocampus, the main site of learning and memory within the brain, is constantly renewed throughout life by a pool of dividing stem cells. A second discrete pool of stem cells generates daughter cells that can migrate to sites of brain damage to facilitate repair. Unfortunately, for reasons that are not currently understood, these migrating stem cells fail to produce enough new neurons in the damage site to provide substantial recovery.

Novogen adopted the alternative approach of seeking drugs that would promote the migration of stem cells to the site of injury, seek to retain those stem cells at the damaged site, and then promote their regenerative capacities. This offered the potential of a non-invasive, well-tolerated, medicinal approach to a widespread problem.

In April 2014, Novogen established a partnership with Genea Biocells, an Australian company with world-leading expertise in the production, growth and development of human embryonic stem cells. The original purpose of that collaboration was to mine the Company's super-benzopyran drug technology platform for new therapies with the capacity to repair aberrant stem cells in people with various neurodegenerative and musculedegenerative disorders such as muscular dystrophies and motor neurone diseases.

That program recently was extended to look at the ability of that same drug platform to stimulate the growth of healthy brain stem cells to create new nerve cells. That has been achieved in what is the first key step in the path to the development of a new family of drugs to treat brain injury.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.

The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate ('Anisina').

Further information is available on our websites www.novogen.com


SOURCE Novogen Ltd

[DomRuinart]

ASX RELEASE
29 January 2015
NASDAQ ACCEPTS NOVOGEN PLAN TO COMPLY WITH NASDAQ LISTING RULES
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced that Nasdaq has approved the Company's definitive plan evidencing its ability to achieve and sustain compliance with the minimum stockholders' equity rule required by Nasdaq. Accordingly, Nasdaq has determined to grant the Company an extension of time to further demonstrate compliance with the rule. Under the terms of the extension, Novogen must furnish to the SEC and Nasdaq, on or before May 6, 2015, a publicly available report providing specified disclosures and affirmations. Novogen intends for the disclosures set forth therein, and in the corresponding current report on Form 6-K filed with the SEC on the date thereof, to satisfy those extension requirements.
Prior Deficiency Notice
Novogen publicly announced on November 12, 2014 that it had received a notice on November 7, 2014 from the Nasdaq Stock Market indicating the Company was not in compliance with the Nasdaq requirement for continued listing because the Company did not have: (i) a minimum of $2,500,000 in stockholders' equity as of June 30, 2014; (ii) at least $35,000,000 market value of listed securities, or (iii) at least $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. Nasdaq requires compliance with one of the foregoing criteria for continued inclusion under Nasdaq Listing Rule 5550(b). Nasdaq stated in its notice that it was reviewing the Company’s eligibility for continued listing on the Nasdaq Capital Market.
Novogen Compliance Plan
In order to facilitate the review, Novogen provided Nasdaq with a specific plan on how it intends to achieve and sustain compliance with the Nasdaq Capital Market listing requirements. The Company’s compliance plan included the completion in November 2014 of a A$1.5 million equity private placements through an offering of ordinary shares and options and in December 2014 of a A$5.6 million equity private placements through an offering of ordinary shares and options to US investors. In connection therewith, Novogen sent a compliance plan to Nasdaq showing stockholders' equity of approximately $6.2 million and a cash position of approximately $8M as of January 19, 2015.
As of the date of this release, Novogen believes that it has regained compliance with the stockholders' equity requirement based on completion of the capital raises described above. Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders' equity requirement.
Graham Kelly PhD, Novogen Group CEO and Executive Chairman, said, “We regard ourselves as a joint Australian-US company. To that end we intend to maintain our dual listing on both the Australian Securities Exchange and Nasdaq. Novogen is pursuing a strategy of growing both its presence and its shareholder base in the US. By the end of 2015 we anticipate the majority of our stock being traded on Nasdaq as ADRs.”

[15000]

Antwort auf Beitrag Nr.: 48.927.794 von DomRuinart am 29.01.15 21:03:10

+50%
neue studie
http://www.theage.com.au/business/markets/quotes/announcemen…

[JazzConsulting]

Explosion Nachbörslich in Amerika. Da könnten wir heute nochmals am normalen Handelstag eine Fortführung sehen!

[NurFundamentalesIstBares]

Antwort auf Beitrag Nr.: 49.233.122 von JazzConsulting am 04.03.15 08:32:07

Vorsicht ist geboten

Ich habe mir gerade mal intensiv das Szenarrio vom 16.12.14 angeschaut (FX AUD/USD, Veröffentlichungszeitpunkte AU/US etc. pp) sowie den CEO letter von gestern Mittag AU-Zeit.

Meine Meinung: hier ist Vorsicht geboten. Kann sein, dass es heute zu Beginn auf über 5 USD geht, kann aber auch sein, dass es anschließend um 40% runter geht, und dann stünde die wieder unter 3 USD.

Man kann denke ich mit einer kleinen Posi rein und mit 20% wieder raus, aber mehr ist zu riskant

nmM